Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1618-1624

  Tang, Y ^a   Yang, H ^b   Qiu, Jianping ^a  

^a Gongli Hospital   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atrial Fibrillation; Brain Natriuretic Peptide; Electrical Cardioversion; Meta Analysis; Recurrence

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIOVERSION; DISEASE ASSOCIATION; DISEASE DURATION; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT DISEASE; SCORING SYSTEM; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 80155144472     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900504     Document Type: Article

References (26)

1. Korantzopoulos P, Kolettis TM, Goudevenos JA, et al: Errors and pitfalls in the non-invasive management of atrial fibrillation. Int J Cardiol 2005; 104: 125-130.
2. Kurita T, Motoki K, Yasuoka R, et al: Rhythm control should be better for the management of patients with atrial fibrillation and heart failure-rhythm control vs. rate control: which is better in the management of atrial fibrillation? (rhythm-side). Circ J 2011; 75: 979-985.
3. Ehrlich JR, Nattel S: Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009; 69: 757-774.
4. Sahin T, Ural D, Kilic T, et al: Right atrial appendage function in different etiologies of permanent atrial fibrillation: a transesophageal echocardiography and tissue Doppler imaging study. Echocardiography 2010; 27: 384-393.
5. Sahin T, Ural D, Kilic T, et al: Evaluation of left atrial appendage functions according to different etiologies of atrial fibrillation with a tissue Doppler imaging technique by using transesophageal echocardiography. Echocardiography 2009; 26: 171-181.
6. Thejus J, Francis J: N-terminal pro-brain natriuretic peptide and atrial fibrillation. Indian Pacing Electrophysiol J 2009; 9: 1-4.
7. Silvet H, Young-Xu Y, Walleigh D, et al: Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003; 92: 1124-1127.
8. Inoue S, Murakami Y, Sano K, et al: Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6: 92-96.
9. Mabuchi N, Tsutamoto T, Maeda K, et al: Plasma cardiac natriuretic peptide as a biological marker of recurrence of atrial fibrillation in elderly people. Nippon Ronen Igakkai Zasshi 2000; 37: 535-540 [in Japanese, English abstract].
10. Buob A, Jung J, Siaplaouras S, et al: Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 559-563.
11. Beck-da-Silva L, de Bold A, Fraser M, et al: Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004; 20: 1245-1248.
12. Lellouche N, Berthier R, Mekontso-Dessap A, et al: Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol 2005; 95: 1380-1382.
13. Kallergis EM, Manios EG, Kanoupakis EM, et al: Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol 105: 90-94.
14. Falcone C, Buzzi MP, D'Angelo A, et al: Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 23: 917-925.
15. Möllmann H, Weber M, Elsässer A, et al: NTProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 2008; 72: 921-925.
16. Tveit A, Seljeflot I, Grundvold I, et al: Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009; 131: 234-239.
17. Watanabe E, Arakawa T, Uchiyama T, et al: High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346-353.
18. Lombardi F, Tundo F, Belletti S, et al: C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. J Cardiovasc Med (Hagerstown) 2008; 9: 581-588.
19. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
20. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
21. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
22. Ogawa Y, Itoh H, Nakao KL: Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 1995; 22: 49-53.
23. Tuinenburg AE, Brundel BJ, Van Gelder IC, et al: Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 827-835.
24. Silvet H, Young-Xu Y, Walleigh D, et al: Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003; 92: 1124-1127.
25. Watanabe M, Murakami M, Furukawa H, et al: Decreased plasma brain natriuretic peptide levels after a successful maze procedure. J Heart Valve Dis 2003; 12: 287-291.
26. Moe GW: B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208-214.